Compare Albertsons Companies Inc (ACI) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Quest Diagnostics Inc — how do they compare? Albertsons Companies Inc trades at $12.05 (market cap $5.95B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 4.4× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ACI | DGX | |
|---|---|---|
Market Cap | $5.95B | $26.21B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $238.50 |
52-Week Low | $11.03 | $173.49 |
Enterprise Value | $21.35B | $31.97B |
Dividend Yield | 5.55% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $11.98, down 1.24% with bearish technical signals despite recent insider buying by the CEO and CFO. The stock shows mixed fundamentals with strong revenue growth to $80.39B in 2025 but declining net margins to 0.08%. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple legal investigations. Analyst consensus remains cautious with a $13.20 price target and 56.52% hold rating.
ACI presents a high-risk opportunity trading near multi-year lows with potential upside to analyst targets. Key catalysts include ACI Edge restructuring and digital initiatives, but investors face significant execution risks amid margin pressure and competitive grocery markets. The stock's deep value case is complicated by earnings volatility and ongoing legal scrutiny.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
